Bone marrow or peripheral blood-derived stem cells for treatment of myocardial ischemia

This study aims to evaluate long term results of autologous intramyocardial transplantation of bone marrow-derived mononuclear cell (BM-MNCs) or peripheral blood-derived stem cell in patients with severe ischemic heart failure. Intra-myocardial bone marrow cell administration found to be safe and feasible. Bone marrow cell transplantation resulted in the substantial improvement of survival, anginal symptoms, LV function and less hospital admissions. Cell transplant improved myocardial perfusion in ischemic segments.